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ABSTRACT
Diabetic kidney disease is one of the most common 
complications of diabetes. For many years, it has also 
been the most common cause of end stage renal dis-
ease. The diagnosis of DKD is based on determining 
the urinary albumin-to-creatinine ratio and calculating 
the estimated glomerular filtration rate. Recently, the 
disease phenotype has changed and instead of the clas-
sical diabetic kidney disease presentation characterized 
by albuminuria followed by progressive renal failure, 
patients nowadays more often present only with re-
duced eGFR but normal urinary albumin excretion. The 
nephroprotective properties of new antidiabetic drugs, 
such as sodium-glucose co-transporter-2 inhibitors and 
glucagon-like peptide-1 analogues, are the novelty of 
recent years. Moreover, there are ongoing outcome 
trials with renal safety as the primary endpoint, and 
their results may extend the knowledge about using 
antidiabetic drugs for renal risk reduction not only in 
patients with diabetes but also in those without car-
bohydrate metabolism disorders. (Clin Diabetol 2020; 
9; 3: 184–188)
Key words: diabetes mellitus, diabetic kidney 
disease, microangiopathy
Introduction
Over the last several decades, diabetic kidney 
disease (DKD) has become the major cause of end 
stage renal disease (ESRD) in the developed countries 
[1, 2]. This microangiopathic complication of diabetes 
develops in about 30% of patients with type 1 diabetes 
mellitus (T1DM) and about 40% of patients with type 2 
diabetes mellitus (T2DM) [1, 3]. An increased DKD inci-
dence reflects a dramatic rise in the number of diabetic 
patients, and therefore diabetes has been dubbed the 
non-infectious epidemics of the 21st century [4]. It has 
been estimated that in 2017 the number of adults with 
diabetes worldwide was 451 million (including more 
than 2.2 million in Poland), and this number is predicted 
to increase to 693 million by 2045 [5]. The natural his-
tory of DKD was believed to begin with hyperfiltration 
followed by microalbuminuria, overt albuminuria, and 
reduction in the glomerular filtration rate, ultimately 
leading to ESRD [6], but in the recent years, it has been 
questioned as this complication has become increas-
ingly heterogeneous. It is currently believed that the 
phenotype of DKD evolves, with an increasing number 
of patients with T2DM who present with a reduced 
estimated glomerular filtration rate (eGFR) without con-
comitant albuminuria [7]. In addition, the development 
of DKD in both T1DM [8] and T2DM [9] is associated 
with an increased cardiovascular event rate and mor-
tality. Thus, a reduction in the risk of DKD’s occurance 
and/or its progression is vital for reducing the risk of 
both cardiovascular mortality and the development of 
ESRD requiring renal replacement therapy. The conven-
tional multifactorial approach to the management of 
DKD includes lifestyle modifications, optimal control 
of diabetes, blood pressure and lipid profile, and the 
use of renin-angiotensin-aldosterone (RAA) system 
inhibitors. Recently, however, large cardiovascular out-
come trials (CVOT) of new antidiabetic drugs, such as 
sodium-glucose co-transporter-2 (SGLT2) inhibitors and 
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glucagon-like peptide-1 (GLP-1) analogues, have shed a 
new light on the benefits of these drugs for the reduc-
tion of not only cardiovascular but also renal risk [10]. 
The present article discusses the most important 
aspects of DKD diagnosis and management based on 
the evidence reported in recent years. 
Diagnosis of DKD
As DKD remains asymptomatic for a long time, 
an extremely important aspect of managing diabetic 
patients is screening for DKD, which should be repeated 
annually since the diagnosis of T2DM and starting 
from 5 years after the diagnosis of T1DM [11]. The 
diagnosis of DKD is based on the clinical evaluation 
including the presence of albuminuria and a reduced 
eGFR [11]. Currently, the preferred approach to the 
evaluation for albuminuria is a measurement of the 
urinary albumin-to-creatinine ratio (UACR) [11, 12] in 
a spot urine sample, preferably collected in the morn-
ing hours. The Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula should be used for 
eGFR calculations [12–14]. Large cross-sectional studies 
showed that many patients with T2DM and a reduced 
eGFR had normal urinary albumin excretion. In these 
studies, the proportion of subjects with normoalbumi-
nuria despite a reduced eGFR (< 60 mL/min/1.73 m2) 
ranged from 16% to 33% [15–18]. These observations 
were also confirmed in patients with T1DM [19], with 
the proportion of patients with normoalbuminuria 
and a reduced eGFR up to as much as 50–60% in some 
studies [20–22]. The proposed explanations include im-
proved blood glucose and blood pressure control, and 
a widespread use of RAA system inhibitors [23]. Thus, 
although the rate of ESRD in diabetes has not changed, 
the DKD phenotype evolved from a classical one, associ-
ated with albuminuria, to the one with normal urinary 
albumin excretion observed in some patients [24]. 
Also of note, the rate of nondiabetic chronic kidney 
disease (CKD) has increase secondary to an increasing 
mean life expectancy, unhealthy lifestyle, and more 
frequent acute kidney injury events of both ischaemic 
and toxic aetiology [25–27]. Due to these factors, CKD 
in diabetic patients is partially related to the presence 
of non-diabetic kidney disease. Thus, CKD in diabetic 
patients may be “pure” DKD (resulting from diabetes 
per se), non-diabetic kidney disease, or a combination 
of diabetic and non-diabetic kidney disease, and these 
types may be truly distinguished only based on renal 
biopsy findings [28]. In the largest study to date that 
evaluated renal biopsy samples in patients with T2DM, 
including 620 patients with the mean diabetes dura-
tion of 10 years, DKD was identified in 37% of renal 
biopsy samples, non-diabetic kidney disease in 36%, 
and concomitant diabetic and non-diabetic kidney 
disease in 27% [29]. However, renal biopsy, although 
considered a diagnostic gold standard, is not a routine 
diagnostic method in the evaluation of DKD and thus 
for the statistical and registry purposes, patients are 
generally categorized as having DKD if they have been 
diagnosed with both diabetes and CKD.
Management of DKD
The major issue in diabetes is to define the princi-
ples of a long-term, safe, well-tolerated and effective 
therapy in patients with a varying degree of vascular 
complications. Antidiabetic drugs, in particular new 
molecules, should not only affect blood glucose control 
but also contribute to a reduction in cardiovascular 
and renal morbidity and mortality. For this reason, the 
U.S. Food and Drug Administration’s (FDA) scientific 
advisory committee published a document in Decem-
ber 2008 that mandated the need for cardiovascular 
risk assessment (performing CVOT) for all the novel 
antidiabetic drugs. These studies must be powered to 
show no excess cardiovascular and renal risk (i.e., prove 
cardiovascular and renal safety) of antidiabetic drugs 
compared to placebo. As CKD, and in particular DKD, 
is associated with an increased cardiovascular risk and 
mortality in both T1DM [8] and T2DM [9], the goal 
of the therapy includes both reducing progression of 
DKD and preventing the development of cardiovascular 
disease [31]. To achieve these goals, a multifactorial 
approach to the management of DKD should include 
lifestyle modifications and optimal control of blood 
glucose, blood pressure (including use of RAA system 
inhibitors) and lipid profile [32–34]. Until recently, RAA 
system inhibitors were the only drugs with proven ne-
phroprotective properties [35, 36]. However, their use 
continued to be associated with a high residual risk of 
DKD progression and the development of ESRD [37]. 
This stagnation in the area of nephroprotection in DKD 
has ended with the results of CVOT of SGLT2 inhibitors 
and GLP-1 analogues [38–44]. Of SGLT2 inhibitors, 
cardiovascular benefits were proven for dapagliflozin, 
empagliflozin, and canagliflozin in the following studies 
respectively: the Dapagliflozin Effect on Cardiovascu-
lar Events–Thrombolysis in Myocardial Infarction 58 
(DECLARE-TIMI 58) study, the Empagliflozin Cardiovas-
cular Outcome Event Trial in Type 2 Diabetes Mellitus 
Patients (EMPA-REG OUTCOME), and the Canagliflozin 
Cardiovascular Assessment Study (CANVAS) [38–40]. 
These studies evaluated predefined endpoints in T2DM 
patients with coronary artery disease or at high cardio-
vascular risk. In addition to a significant reduction of the 
combined primary endpoint of cardiovascular death, 
non-fatal myocardial infarction, and non-fatal stroke, 
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a significant reduction in hospitalization due to heart 
failure and a significant nephroprotective effects was 
shown, with a relative risk reduction of renal disease 
progression by about 40%. To further substantiate 
these very promising results in regard to nephropro-
tection, subsequent studies with these drugs were 
designed with the primary endpoint of renal disease 
progression. These include: the Dapagliflozin And Pre-
vention of Adverse Outcomes in Chronic Kidney Disease 
(DAPA-CKD) study [45], The Study of Heart and Kidney 
Protection With Empagliflozin (EMPA-KIDNEY) [46], 
and the Canagliflozin and Renal Outcomes in Type 2 
Diabetes and Nephropathy (CREDENCE) study [47]. One 
of these studies, the CREDENCE trial with canagliflozin, 
was terminated earlier than planned due to a proven 
independent nephroprotective effect of the drug, and 
the results were published in April 2019. Canagliflozin 
treatment was shown to result in a significant reduc-
tion of the primary combined endpoint that included 
ESRD (defined as the need for dialysis therapy or kidney 
transplantation, or persistent eGFR reduction to < 15 
mL/min/1.73 m2), doubling of serum creatinine, and 
renal or cardiovascular death. Several months later, 
in September 2019, FDA approved canagliflozin for 
the prevention of ESRD, doubling of serum creatinine, 
cardiovascular mortality, and hospitalizations due to 
heart failure in patients with T2DM, DKD, and albu-
minuria > 300 mg/d [48]. The newest SGLT2 inhibitor 
available in Poland is ertugliflozin, and its CVOT, the 
Cardiovascular Outcomes Following Ertugliflozin Treat-
ment in Type 2 Diabetes Mellitus Participants With Vas-
cular Disease (VERTIS CV) study, is currently underway. 
Regarding GLP-1 analogues, CVOT which first showed 
nephroprotective properties of these drugs based on 
the assessment of secondary endpoints included: the 
Liraglutide Effect and Action in Diabetes: Evaluation 
of Cardiovascular Outcome Results (LEADER) study 
[41], the Semaglutide and Cardiovascular Outcomes in 
Patients with Type 2 Diabetes (SUSTAIN-6) study [42], 
and the Dulaglutide and Cardiovascular Outcomes in 
Type 2 Diabetes (REWIND): A Double-Blind, Randomised 
Placebo-Controlled Trial [44]. These studies revealed 
that GLP-1 analogues contribute to a reduced risk of 
renal function worsening, and their nephroprotective 
effect is mostly related to a reduction in albuminuria. 
To date, no studies of GLP-1 analogues have been pub-
lished that would evaluate a primary endpoint of renal 
safety (reduced CKD progression, reduced mortality due 
to renal causes). The only ongoing trial with a GLP-1 
analogue that evaluates a primary endpoint of renal 
safety is A Research Study to See How Semaglutide 
Works Compared to Placebo in People With Type 2 
Diabetes and Chronic Kidney Disease (FLOW), and its 
results are expected in August 2024 [49]. 
Summary
The above evidence of a beneficial effect of SGLT2 
inhibitors and GLP-1 analogues on the reduction of 
cardiovascular and renal risk led to a modification of 
the therapeutic approach and guidelines on the man-
agement of patients with diabetes. The 2018 consen-
sus of the American Diabetes Association (ADA) and 
the European Association for the Study of Diabetes 
(EASD) [50] first highlighted the need for combining 
the previously recommended multifactorial approach 
based on the results of STENO and STENO 2 (Intensi-
fied Multifactorial Intervention in Patients With Type 2 
Diabetes and Microalbuminuria) studies [32, 51] with 
treatment individualization based on the presence of 
cardiovascular disease, CKD, an elevated risk of hypo-
glycemia, the need for weight reduction, and economic 
restraints. It should be noted that cardiovascular and 
renal safety are intrinsically and bidirectionally related 
and cannot be considered separately. In an update of 
the 2018 ADA/EASD consensus that was published in 
December 2019, it was suggested that adding an SGLT2 
inhibitor or a GLP-1 analogue to metformin should 
be considered regardless of baseline HbA1c value in 
T2DM patients at high cardiovascular risk to reduce 
the risk of major adverse cardiovascular events (MACE), 
hospitalizations due to heart failure, cardiovascular 
mortality, and CKD progression, and these recom-
mendations have been echoed in the 2020 Diabetes 
Poland guidelines [52, 53]. According to them, GLP-1 
analogues with proven cardio- and nephroprotective 
properties should be preferentially used in patients with 
an atherosclerotic cardiovascular disease, and SGLT2 
inhibitors should be preferred in patients with a heart 
failure and reduced ejection fraction (< 45%) or CKD 
(eGFR 30–60 mL/min/1.73 m2 or UACR > 30 mg/g). The 
2020 Diabetes Poland guidelines do not recommend 
using SGLT2 inhibitors in patients with eGFR below 60 
mL/min/1.73 m2 yet. The ongoing trials should clarify in 
the near future whether these drugs may be indicated 
for nephroprotection also in primary prevention, and 
also in subjects without diabetes.
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